Alnylam Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$302.94
Cap
—
Earnings
—
30d Trend
-0.5%
36% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 41×Macro 0.99 (−1%)=41
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Alnylam Pharmaceuticals, Inc. at 41/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 75/100. I classify this as a defensive position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+1.3%
3 MONTHS
-8.4%
12 MONTHS
+4.2%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Quality (75) and Technical (49) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is moderate at 36%. I classify this as a defensive holding — stability characteristics and high business quality provide portfolio ballast.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.